Abstract: This invention concerns novel receptor protein tyrosine phosphatase polypeptides. Specifically, this invention concerns the novel receptor protein tyrosine phosphatase .lambda. which is related to the homotypically adhering receptor protein tyrosine phosphatases .kappa. and .mu.. The invention further relates to analogs of these polypeptides in other mammals, functional derivatives thereof, antibodies which are capable of specifically binding to these polypeptides, nucleic acids encoding these polypeptides, vectors containing and capable of expressing such nucleic acid and recombinant host cells transformed with such nucleic acid. Methods for the recombinant production of these receptor protein tyrosine phosphatase polypeptides and assays for identifying agonists and antagonists of these polypeptides are also within the scope of the invention.
Abstract: A polypeptide which has the activity of an inhibitor DE-3 from Erythrina caffra and which reversibly and selectively binds serine proteases from a protein mixture is obtainable by culturing prokaryotic or eukaryotic host cells which have been transformed or transfected with a nucleic acid that codes for the said polypeptide in a manner that allows the host cells to express the said polypeptide under suitable nutrient conditions and isolating the said polypeptide, wherein the polypeptide has an amino acid sequence which is functionally analogous to SEQ ID NO:2, has a partial region that is more than 85% homologous to the region of amino acids 39-139 of this sequence, has two disulfide bridges and begins N-terminally with SEQ ID NO:4 or with a SEQ ID NO:4 extended N-terminally by methionine and has a binding capacity for tissue plasminogen activators of 1.25 MU/ml and more and is particularly suitable for purifying plasminogen activators such as tissue plasminogen activators (t-PA and derivatives).
Type:
Grant
Filed:
October 3, 1997
Date of Patent:
October 26, 1999
Assignee:
Roche Diagnostics GmbH
Inventors:
Ulrich Kohnert, Anne Stern, Manfred Wozny, Stephan Fischer
Abstract: The invention features nucleic acid molecules and methods for use in site-specific methylation of ribonucleotides. The methods of the invention can be used to modulate RNA folding, RNA processing, RNA cleavage, and other processes involving sequence-specific recognition of RNA sequences, as well as for promoting RNA stability.
Abstract: Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
Abstract: A pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising recombinant coagulation factor VIII and use thereof for manufacture of a medicament for treating haemophilia is provided. The formulation comprises a highly purified recombinant coagulation factor VIII in a concentration of at least 1000 IU/ml, which gives surprisingly high levels of active factor VIII in the blood stream after subcutaneous, intramuscular or intradermal administration. The formulation is intended for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration. The recombinant factor VIII is preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.
Type:
Grant
Filed:
December 21, 1995
Date of Patent:
October 26, 1999
Assignee:
Pharmacia & Upjohn Aktiebolag
Inventors:
Jack Spira, Lars Widlund, Thomas Osterberg
Abstract: The present invention relates to polypeptide having a primary structure of amino acid sequence shown by Sequence List Sequence No. 1 and DNA encoding for the polypeptide. The polypeptide is obtainable by following steps (1)-(3):Step (1): extracting small granule fraction of homocytes of horseshoe crab with a buffer containing protein denaturing agent and chelating agent,Step (2): subjecting said extract to reverse phase high performance liquid chromatography,Step (3): eluting by concentration gradient elution with a hydrophobic organic solvent.Also, the polypeptide is produced by chemical synthesis. The polypeptide has similar chemical structure to defensin and is useful as gargles, disinfectants, antiseptics or antimicrobials.
Abstract: The invention provides the DNA and amino acid sequence of dUTPase, an enzyme which is essential for life and which is increased during periods of cellular proliferation. The human form of the dUTPase enzyme has been found to have two isoforms, a nuclear and a mitochondrial isoform. Methods of determining the proliferation status of a cell, efficacy of antineoplastic compounds, and response to therapy with antineoplastic compounds, using cellular levels of dUTPase is disclosed. A kit containing the necessary reagents for the determination of dUTPase is also disclosed.
Type:
Grant
Filed:
March 26, 1997
Date of Patent:
October 5, 1999
Assignee:
The University of Medicine and Dentistry of New Jersey
Inventors:
Robert D. Ladner, Frank Lynch, Salvatore J. Caradonna
Abstract: The present invention provides a novel protein tyrosine kinase (HPTYK) and polynucleotides which identify and encode HPTYK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPTYK and a method for producing HPTYK. The invention also provides pharmaceutical compositions containing HPTYK or antagonists to HPTYK, and for the use of these compositions in the treatment of diseases associated with the expression of HPTYK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPTYK for the treatment of diseases associated with the expression of HPTYK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HPTYK or antibodies which specifically bind to HPTYK.
Abstract: Novel .alpha.-amylase enzymes are disclosed in which one or more asparagine residues are substituted with a different amino acid or deleted. The disclosed .alpha.-amylase enzymes show altered or improved low pH starch hydrolysis performance, stability and activity profiles.
Type:
Grant
Filed:
February 20, 1997
Date of Patent:
September 28, 1999
Assignee:
Genencor International Inc.
Inventors:
Colin Mitchinson, Carol Requadt, Traci Ropp, Leif P. Solheim, Christopher Ringer, Anthony Day
Abstract: The DNA encoding glucan synthesis gene 1 (GLS1) is cloned and used in an in vitro assay to screen for compounds that modulate 1,3 .beta.-D glucan synthase activity.
Type:
Grant
Filed:
November 21, 1996
Date of Patent:
September 21, 1999
Assignee:
Merck & Co., Inc.
Inventors:
Mohammed El-Sherbeini, Joseph A. Clemas
Abstract: Novel protein tyrosine phosphatases in which the invariant aspartate residue is replaced with an alanine residue and which bind to a tyrosine phosphorylated substrate and are catalytically attenuated are described. Also described are methods of identifying tyrosine phosphorylated proteins which complex with the described protein tyrosine phosphatases.
Abstract: The present invention relates to a novel proteinase inhibitor useful as a medicine or pesticides and a gene coding for the inhibitor. A proteinase inhibitor (Kexstatin) having inhibitory activity against Kex2 proteinase family enzymes and having a molecular weight of 11,500; a gene coding for Kexstatin; and a method for producing Kexstatin using a microorganism belonging to the genus Streptomyces or transformed with Kexstatin gene are disclosed.
Type:
Grant
Filed:
June 19, 1997
Date of Patent:
September 14, 1999
Assignee:
Biomolecular Engineering Research Institute
Inventors:
Yuji Shibano, Norihisa Kikuchi, Kohei Oda
Abstract: The present invention generally provides polypeptides that are related to and/or derived from the family of PI3-kinases. These polypeptides are generally involved in cell signaling cascades which control, e.g., cell cycle progression and intracellular protein sorting. The family of PI3-kinases from which the polypeptides of the invention are derived are generally characterized by their structure as well as their unique substrate specificity.
Type:
Grant
Filed:
February 12, 1996
Date of Patent:
September 7, 1999
Assignee:
The Regents of the University of California
Inventors:
Lewis T. Williams, Lisa Molz, Yen-Wen Chen
Abstract: A stamp for transferring molecules and molecular patterns to a substrate face includes a backing and a polymeric gel bound to the backing and loaded with the a molecular species. Where the molecule to be patterned is a biomolecule, such as a protein or nucleic acid, the polymeric gel is typically a hydrogel. Exemplary hydrogels include sugar-based polyacrylates and polyacrylamides.
Type:
Grant
Filed:
September 30, 1997
Date of Patent:
September 7, 1999
Assignee:
The United States of America as represented by the Secretary of the Navy
Inventors:
David C. Turner, Brett Martin, Bruce P. Gaber
Abstract: The present invention relates to a process for synthesizing oligosaccharides. The process involves contacting an acceptor moiety with unpurified sugar-nucleotides and/or unpurified glycosyltransferase to synthesize oligosaccharides.
Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus nidulans. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus nidulans atrC are also provided. The invention further provides assays which utilize these transformed host cells.
Type:
Grant
Filed:
December 23, 1997
Date of Patent:
August 31, 1999
Assignee:
Eli Lilly and Company
Inventors:
Paul Luther Skatrud, Maarten A. de Waard, Alan C. Andrade, Robert Brown Peery
Abstract: Novel FMCP polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length FMCP proteins, the invention further provides isolated FMCP fusion proteins, antigenic peptides and anti-FMCP antibodies. The invention also provides FMCP nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a FMCP gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
Abstract: The present invention relates to the biosynthesis of .beta.-lactam antibiotics. More specifically, the invention relates to processes of producing .beta.-lactam antibiotics in vivo and in vitro. Also contemplated is a novel enzyme capable of catalyzing certain steps involved in .beta.-lactam biosynthesis. Further, the invention relates to a DNA construct encoding the novel enzyme, a recombinant vector or transformation vehicle comprising the DNA construct, and finally a cell comprising the DNA construct or recombinant vector.
Type:
Grant
Filed:
June 19, 1997
Date of Patent:
August 24, 1999
Assignee:
Gist-Brocades
Inventors:
Svend Kaasgaard, Klaus N. Kristiansen, Henrik M.o slashed.lgaard
Abstract: Modified thermostable DNA polymerases having enhanced efficiency for incorporating unconventional nucleotides, such as ribonucleotides, into DNA products, are advantageous in many in vitro synthesis applications. Such enzymes are particularly useful for use in nucleic acid sequencing protocols and provide novel means for DNA sequence analysis. Genes encoding the modified enzymes and methods for their production and use offer cost and efficiency advantages for DNA sequencing.
Type:
Grant
Filed:
August 5, 1997
Date of Patent:
August 17, 1999
Assignee:
Roche Molecular Systems, Inc.
Inventors:
David Harrow Gelfand, Lisa Vivian Kalman, Fred Lawrence Reichert
Abstract: The present invention relates to novel strains of Escherichia coli and fermentation processes involving these microorganisms. More specifically, the present invention relates to genetically-modified Escherichia coli strains and the use thereof for the production of the amino acids, particularly members of the aspartate family of amino acids such as threonine. The present invention also relates to methods of preparing E. coli strains for use in the fermentative production of amino acids.
Type:
Grant
Filed:
July 29, 1997
Date of Patent:
August 17, 1999
Assignee:
The Archer-Daniels-Midland Company
Inventors:
Ming-Der Wang, Jill S. Bradshaw, Stacia L. Swisher, Hungming James Liaw, Paul D. Hanke, Thomas P. Binder